Mitch Gold, M.D.

Mitch joined Frazier Life Sciences as a Venture Partner in 2025, bringing over 25 years of experience as a successful biotech executive.

Mitch is a Venture Partner at Frazier Life Sciences, where he is focused on company creation opportunities. He is currently on the board of Attovia Therapeutics.

Mitch was most recently Alpine Immune Sciences Co-Founder, CEO, and the Executive

Chairman of Alpine’s Board of Directors since the company was founded in January 2015 until its sale to Vertex Pharmaceuticals in May of 2024 for $4.9 billion.

Prior to co-founding Alpine Immune Sciences, Mitch was the Chairman and Founder of Alpine Biosciences, a privately held biotech company dedicated to developing the next generation of cancer and orphan disease treatments. Alpine Biosciences was sold to Cascadian Therapeutics in 2014 which was subsequently acquired by SGEN. Both Alpine Immune Sciences and Alpine Biosciences received their seed funding from Alpine Bioventures, a venture capital firm Mitch founded in 2012 focused on new company creation.

Earlier in his career, Mitch was the CEO and Chairman of Dendreon Corporation, where he

and his team developed the world’s first cell-based therapy to be approved by the FDA. Dendreon ushered in an entirely new era in cancer treatments with the FDA approval of PROVENGE® (sipuleucel-T), in April 2010.

Mitch holds an M.D. from Rush Medical College in Chicago and did his Urology Residency at the  University of Washington Medical Center, and holds a B.S. in Biology from the University of Wisconsin-Madison.